A new treatment for people with multiple myeloma will now be available on the NHS in England.

Daratumumab (Darzalex) was approved by the National Institute of Health and Care Excellence (NICE) in combination with two other drugs, bortezomib (Velcade) and dexamethasone, after the treatment was found to extend the time that patients lived without their cancer getting worse.

NICE recognised DVd as a ‘game-changing’ treatment, which improves overall survival and reduces the risk of death by 50%.

Read the full article by Cancer Research UK here.